Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKinsey
Express Scripts
Dow
Medtronic

Last Updated: December 12, 2019

DrugPatentWatch Database Preview

Angiotensin ii acetate - Generic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What are the generic sources for angiotensin ii acetate and what is the scope of freedom to operate?

Angiotensin ii acetate is the generic ingredient in one branded drug marketed by La Jolla Pharma and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Angiotensin ii acetate has eleven patent family members in eleven countries.

There are five drug master file entries for angiotensin ii acetate. One supplier is listed for this compound.

Summary for angiotensin ii acetate
Recent Clinical Trials for angiotensin ii acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Heart, Lung, and Blood Institute (NHLBI)Phase 2
Johns Hopkins UniversityPhase 2
American Lung AssociationPhase 2

See all angiotensin ii acetate clinical trials

Pharmacology for angiotensin ii acetate
Drug ClassVasoconstrictor
Physiological EffectVasoconstriction
Medical Subject Heading (MeSH) Categories for angiotensin ii acetate
Synonyms for angiotensin ii acetate
(Ile5)-Angiotensin II acetate
31L3HS630A
68521-88-0
AC1L58RQ
Angiotensin II [USAN]
Angiotensin II acetate (USAN)
Angiotensin II acetate [USAN]
Angiotensin II human acetate salt
Angiotensin II, 5-L-isoleucine-, acetate (salt)
Angiotensin II, human acetate salt
CHEMBL3989932
CTK2F5080
D11142
Giapreza (TN)
Human angiotensin II acetate salt
SCHEMBL1585377
UNII-31L3HS630A

US Patents and Regulatory Information for angiotensin ii acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-002 Dec 21, 2017 DISCN Yes No   Start Trial   Start Trial   Start Trial
La Jolla Pharma GIAPREZA angiotensin ii acetate SOLUTION;INTRAVENOUS 209360-001 Dec 21, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Boehringer Ingelheim
Medtronic
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.